The other FDA-approved ADC uses the chimeric mAb brentuximab to target the CD30 antigen, which is expressed at high density on the malignant Hodgkin and Reed-Sternberg (HRS) cell in HL and on the non-HL cells of ALCL. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.